PALI

Business Context and Reporting Period

Company: Neuralstem, Inc. (Note: Metadata listed "Palisade Bio," but filing text confirms Neuralstem, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: Neuralstem is a clinical-stage biotechnology company focused on developing treatments based on human neural stem cells and small molecule compounds. The company has no commercial revenue and relies on external financing. Key activities include a Phase I clinical trial for Amyotrophic Lateral Sclerosis (ALS) and pre-clinical development of a small molecule for depression.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Income to Loss: The company swung from a net income of $905,678 in Q1 2009 to a net loss of $6.77 million in Q1 2010. The 2009 income was driven by a non-cash gain of $3.8 million from a decrease in the fair value of warrant liabilities. In Q1 2010, this reversed to a loss of $1.25 million due to an increase in stock price affecting remaining warrant liabilities.
• Warrant Accounting: Significant non-cash expenses were recorded in Q1 2010, including $1.9 million in warrant issuance and modification expenses and a $1.25 million loss on the change in fair value of warrant obligations.
• Operating Expenses: Total operating expenses increased by approximately 24% ($704,817) year-over-year. Research and Development (R&D) costs rose 33% to $1.9 million, primarily due to the initiation of the ALS clinical trial. General and Administrative (G&A) expenses increased 16% to $1.7 million, driven by higher legal fees.
• Liquidity: Cash balances increased by $3.95 million (111%) compared to the prior year, primarily due to the exercise of outstanding warrants which generated $7.38 million in financing proceeds.

Guidance, Outlook, and Risks

• Outlook: Management does not anticipate revenue in 2010. The focus remains on the ALS Phase I trial (estimated cost $130,000 per patient) and preparing an Investigational New Drug (IND) application for Spinal Cord Injury in 2010. An IND for a small molecule depression treatment is expected in early 2011.
• Liquidity Needs: The company reported a monthly cash burn rate of approximately $600,000. Management believes current cash reserves ($7.5 million) are sufficient to fund operations into the first quarter of 2011. Additional capital will be required to sustain operations and development.
• Listing Status: The company is under monitoring by the NYSE Amex regarding listing qualifications. While they resolved specific deficiencies in February 2010, they remain non-compliant with stockholders' equity requirements and must demonstrate compliance over two consecutive quarters ending June 30, 2010, to close the "Plan Period."
• Legal Proceedings: Ongoing patent litigation with StemCells, Inc. regarding stem cell culture compositions. The outcome is uncertain and could be costly.
• Key Risks: Dependence on a single product candidate (ALS), inability to raise additional capital, failure of clinical trials, and potential delisting from the NYSE Amex.

Investor Verification Checklist

• Cash Runway: Verify if the $600,000 monthly burn rate remains accurate given the ongoing clinical trial costs.
• Warrant Liability: Monitor the fair value of remaining warrant obligations, as stock price volatility directly impacts net income/loss.
• Listing Compliance: Confirm the company's status regarding NYSE Amex listing requirements by the June 30, 2010 deadline.
• Clinical Trial Progress: Track enrollment and safety data for the ALS Phase I trial, as failure here would severely impact the business model.
• Capital Raising: Assess the company's ability to raise additional funds before Q1 2011, noting the potential for significant shareholder dilution.